• Natera, Inc. recently reported that Monica Bertagnolli resigned from its Board of Directors on July 1, 2026, following her appointment to the National Academy of Medicine, with the company confirming her departure was unrelated to any disagreement over operations, policies, or practices.
• The company also announced new JAMA Oncology data from the GALAXY arm of CIRCULATE-Japan showing its Signatera MRD test can help identify which patients with resected colorectal liver metastases gain meaningful survival benefits from adjuvant chemotherapy, potentially reinforcing Signatera’s clinical utility in oncology care decisions.
• We’ll now examine how this new JAMA Oncology evidence for Signatera’s role in guiding adjuvant chemotherapy could influence Natera’s investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Natera Investment Narrative Recap

To own Natera, you need to believe in broad adoption of molecular residual disease (MRD) testing and continued validation of Signatera across cancer settings, while accepting ongoing losses and execution risks around reimbursement and trial outcomes. The new JAMA Oncology data strengthens the clinical story for MRD-guided adjuvant chemotherapy but does not appear to change the central near term catalyst of regulatory and payer decisions, nor the key risk of sustained high cash burn.

Among recent updates, the JAMA Oncology publication on Signatera in resected colorectal liver metastases is especially relevant. It adds peer reviewed evidence that Signatera can stratify which MRD positive patients gain survival benefit from adjuvant chemotherapy, which may support future discussions with regulators and payers about coverage and guidelines. For investors focused on MRD as Natera’s core value driver, this dataset sits squarely in the path of the main catalysts they are watching.

Yet, against these positives, investors should also be aware of the risk that high ongoing R&D and SG&A spending could...

Natera’s narrative projects $4.2 billion revenue and $289.0 million earnings by 2029. This requires 18.6% yearly revenue growth and about a $515 million earnings increase from -$226.3 million today.

Uncover how Natera's forecasts yield a $260.05 fair value, a 6% downside to its current price.

Exploring Other Perspectives

Some analysts were already assuming Natera could reach about US$4.7 billion in revenue and US$849 million in earnings by 2029, so if you are weighing this new JAMA MRD evidence, it is worth asking whether those more optimistic expectations or the more cautious concerns about rising compliance and privacy costs now feel closer to your own view.

Explore 4 other fair value estimates on Natera - why the stock might be worth 6% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Natera research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.